CINECA IRIS Institutional Research Information System

GALIMBERTI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 37.279
AS - Asia 18.169
EU - Europa 14.591
SA - Sud America 3.120
AF - Africa 662
OC - Oceania 38
Continente sconosciuto - Info sul continente non disponibili 19
Totale 73.878
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 33.977
SG - Singapore 5.360
CN - Cina 5.186
IT - Italia 5.092
HK - Hong Kong 3.240
CA - Canada 3.051
BR - Brasile 2.593
SE - Svezia 2.317
VN - Vietnam 1.683
DE - Germania 1.189
BG - Bulgaria 1.144
PL - Polonia 1.029
GB - Regno Unito 820
TR - Turchia 711
FR - Francia 672
RU - Federazione Russa 596
FI - Finlandia 568
UA - Ucraina 442
JP - Giappone 387
IN - India 382
KR - Corea 292
CI - Costa d'Avorio 211
CH - Svizzera 202
BD - Bangladesh 179
AR - Argentina 156
MX - Messico 117
IQ - Iraq 111
NL - Olanda 97
EC - Ecuador 94
BE - Belgio 88
ID - Indonesia 88
SN - Senegal 87
AT - Austria 85
PK - Pakistan 83
ZA - Sudafrica 83
UZ - Uzbekistan 82
SA - Arabia Saudita 73
CO - Colombia 57
VE - Venezuela 55
MA - Marocco 52
PY - Paraguay 52
ES - Italia 51
KE - Kenya 46
NG - Nigeria 45
EG - Egitto 38
PH - Filippine 34
CL - Cile 33
UY - Uruguay 31
MY - Malesia 30
AU - Australia 29
CZ - Repubblica Ceca 29
IE - Irlanda 28
PE - Perù 28
IL - Israele 27
AZ - Azerbaigian 26
LT - Lituania 23
JM - Giamaica 22
TN - Tunisia 22
JO - Giordania 21
CR - Costa Rica 20
AE - Emirati Arabi Uniti 19
GR - Grecia 19
KZ - Kazakistan 19
OM - Oman 19
BJ - Benin 18
RO - Romania 18
BO - Bolivia 17
DO - Repubblica Dominicana 17
EU - Europa 16
PS - Palestinian Territory 16
ET - Etiopia 14
NP - Nepal 14
DZ - Algeria 13
TT - Trinidad e Tobago 13
PT - Portogallo 12
NI - Nicaragua 11
DK - Danimarca 10
IR - Iran 10
LB - Libano 10
AL - Albania 9
HN - Honduras 9
PA - Panama 9
HU - Ungheria 8
NZ - Nuova Zelanda 8
TH - Thailandia 8
BB - Barbados 7
BH - Bahrain 7
BY - Bielorussia 7
RS - Serbia 7
TW - Taiwan 7
GE - Georgia 6
EE - Estonia 5
KG - Kirghizistan 5
KW - Kuwait 5
MD - Moldavia 5
PR - Porto Rico 5
SY - Repubblica araba siriana 5
AM - Armenia 4
AO - Angola 4
BS - Bahamas 4
Totale 73.785
Salva come PNG Salva come JPEG
Città #
Ashburn 3.503
Hong Kong 3.196
Woodbridge 3.154
Singapore 2.986
Fairfield 2.512
Dallas 2.436
Ann Arbor 2.393
Montreal 2.329
Houston 2.009
Serra 2.009
San Jose 1.870
Chandler 1.819
Santa Clara 1.677
Milan 1.233
Beijing 1.185
Shanghai 1.157
Sofia 1.137
Seattle 1.101
Wilmington 868
Cambridge 823
New York 815
Boardman 685
Princeton 631
Ottawa 592
Jacksonville 570
Los Angeles 509
Lawrence 455
Ho Chi Minh City 438
Medford 437
Lauterbourg 434
Hefei 424
Izmir 424
Tokyo 341
Nanjing 315
Seoul 275
Hanoi 255
Des Moines 231
Florence 225
London 215
São Paulo 214
Abidjan 210
Istanbul 204
Munich 202
Dearborn 198
Council Bluffs 195
Redondo Beach 185
San Diego 170
Dong Ket 169
Buffalo 166
Rome 160
Bern 159
Nanchang 155
Helsinki 139
Redwood City 120
Frankfurt am Main 114
Jüchen 98
Bremen 94
Pisa 92
Chicago 91
Orem 89
Hebei 88
Lancaster 88
Dakar 87
Brussels 86
Changsha 86
Shenyang 84
Rio de Janeiro 82
Tashkent 75
Kunming 73
Ogden 71
Turku 68
Fuzhou 67
Vienna 63
Da Nang 61
Nuremberg 61
Columbus 58
The Dalles 58
Belo Horizonte 56
Düsseldorf 54
Curitiba 52
Guangzhou 52
Phoenix 51
Boulder 49
Jiaxing 48
Westminster 47
Dhaka 46
Haiphong 45
Porto Alegre 45
Norwalk 44
Chennai 42
Denver 42
Hangzhou 42
Lagos 42
Pune 42
Nairobi 41
Warsaw 41
Baghdad 40
Tianjin 39
Washington 39
Alessandria 38
Totale 53.185
Salva come PNG Salva come JPEG
Nome #
EFFICACY AND TOXICITY PROFILES OF LOW-DOSE THALIDOMIDE AS MAINTENANCE THERAPY IN MULTIPLE MYELOMA PATIENTS AFTER DOUBLE OR TRIPLE AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION. 3.413
Diagnostic applications of nuclear medicine: Multiple myeloma 759
Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes 280
Multidisciplinary Evaluation Improves Efficacy and Safety of Iron Chelation Therapy with Deferasirox in MDS Elderly Patients 262
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases 255
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia 250
Atypical APL including multiple translocations and abnormal response to micronuclei induction test 246
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen. Leuk Lymphoma 237
Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells 235
Bone marrow infiltration in B-cell non-Hodgkin's lymphomas: comparison between flow cytometry and bone marrow biopsy, RECENTI PROGRESSI IN MEDICINA 231
IN THE CHRONIC MYELOID LEUKEMIA THE SALIVARY PROTEOMICS RECAPITULATES SOME ASPECTS OF THE LEUKEMIC STEM CELL. LA CELLULA STAMINALE LEUCEMICA E LA PROTEOMICA SALIVARE: IL MODELLO DELLA LEUCEMIA MIELOIDE CRONICA 230
Correspondence between salivary proteomic pattern and clinical course in primary Sjogren syndrome and non-Hodgkin's lymphoma: a case report 229
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases 225
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 225
Expression of MDR1, MRP, TOPOISOMERASE-IIa, TOPOISOMERASE-IIb and GSTp in acute leukemias. 221
Human autologous plasma-derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing. 220
MESENCHYMAL CELLS INHIBIT IL2 AND ZOLENDRONATE-INDUCED ?/d T-LYMPHOCYTES 218
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia 217
CHEMOIMMUNOTHERAPY REGIMEN OF FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB FOLLOWED BY ALEMTUZUM- AB AS INITIAL THERAPY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA: A VALID APPROACH FOR ERADICATION OF MINIMAL RESIDUAL DISEASE 216
ED-B fibronectin expression is a marker of epithelial-mesenchymal transition in translational oncology 214
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 213
Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment 212
Could age modify the effect of genetic variants in IL6 and TNF-a genes in multiple myeloma? 211
Autoimmune diseases and myeloid hematological disorders: a possible pathogenetic relationship 211
Panobinostat for the treatment of acute myelogenous leukemia 208
EFFICACY OF FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (FCR) REGIMEN FOL- LOWED BY ALEMTUZUMAB AS IN VIVO PURGING TOOL FOR PATIENTS WITH ADVANCED CHRONIC LYMPHOCYTIC LEUKEMIA 206
WT1 GENE EXPRESSION IS SIGNIFICANTLY INHIBITED BY VORINOSTAT AND BORTEZOMIB IN MYELOPROLIFERATIVE/MYELODISPLASTIC DISEASES 206
Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms 205
5-AZACYTIDINE FOR THE TREATMENT OF INTERMEDIATE-2/HIGH IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 83 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM 205
Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemia. 204
EXTENSIVE ANALYSIS OF T CELL RECEPTOR GAMMA (TCRG) GENE REARRANGEMENTS REVEALS A SIMILAR REPERTOIRE IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AND IN HYPEREOSINOPHILIC SYNDROME (HES) 204
Characterization of Ph-negative abnormal clones emerging during imatinib therapy 203
Clinical Applications of Nuclear Medicine: Multiple Myeloma 203
Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib 202
Dipeptidyl-Peptidase 4 (Cd26): a Possible Therapeutic Target in Covid-19 202
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen 201
The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. 201
The combination of rituximab and bendamustine as first-line treatment is highly effective in the eradicating minimal residual disease in follicular lymphoma: An Italian retrospective study 198
Combined unfavourable polymorphisms ofhOCT1 and ABCG2 are responsible for delayed complete cytogenetic response during imatinib treatment. 198
Oral cyclophosphamide therapy for patients with residual or relapsed indolent-type lymphoma after initial treatment for aggressive lymphomas. A sub-group of patients with apparent transformed indolent lymphoma. 197
Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. 197
The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia 197
Carboxy-terminal fragment of osteogenic growth peptide regulates myeloid differentiation through RhoA 196
Unexpected cardiotoxicity in haematological bortezomib treated patients 194
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). 194
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 194
Diagnostic Applications of Nuclear Medicine: Leukemias 193
Polycomb genes are associated with response to imatinib in chronic myeloid leukemia 193
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines 192
GTF2I mutations are common in thymic epithelial tumors but not in hematological malignancies 192
PS-341 (Bortezomid) inhibits both proliferation of megakaryoblastic cells in vitro and MK colonies production in patients affected by idiopathic myelofibrosis 190
Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report in a case of delayed graft failure 189
Role of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) in Inducing and Maintaining Complete Molecular Response in B Non Hodgkin’s Lymphoma Patients in Clinical Complete Remission after Chemotherapy Regimen. 188
Suspension of Bone Marrow-Derived Undifferentiated Mesenchymal Stromal Cells for Repair of Superficial Digital Flexor Tendon in Race Horses. Tissue Eng. 2007 Oct 5 188
2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma 188
Transmembrane Transporters hOCT1 and SLCO1B3 Polymorphisms Could Have a Role in Patients Affected By Chronic Myeloid Leukemia Treated with Nilotinib 188
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment 188
Skin and stomach graft versus host disease after syngeneic BMT in CML: A case report., LEUKEMIA RESEARCH,pp 00,tot.pag 00,tot. autori 7,2007 187
BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) COMBINATION FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF A PHASE II STAUDY. 186
Predictive role of WT1 and RPS14 expression in patients affected by myelodysplastic syndromes receiving azacitidine 186
Association of PIM gene translocation and TELAML1 rearrangement., LEUKEMIA RESEARCH,vol. Leuk Res. 2007 Dec;31(12):1761-2 185
TCR REARRANGEMENTS ARE NOT ENOUGH FOR DISTINGUISHING THE CHURG-STRAUSS SYNDROME FROM THE HYPEREOSINOPHILIC SYNDROME 185
ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview 185
Vascular Endothelial Growth Factor Polymorphisms in Mantle Cell Lymphoma 184
MDS: An Integrated Workup for a Correct Diagnosis 184
TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EGPA FROM HES 184
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol. 2010 Apr;21(4):851-4. Epub 2009 Oct 13. 183
VDTPACE As Salvage Therapy For Heavily Pretreated MM Patients 183
ACUTE T-LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC T-CELL LYMPHOMA. ROLE OF EARLY allo-SCT 183
INDUCTION OF COMPLETE MOLECULAR RESPONSE WITH YTTRIUM-90 IBRITUMOMAB TIUXETAN (ZEVALIN®) IN B CELL NON HODGKIN’S LYMPHOMA PATIENTS AFTER THE ACHIEVEMENT OF A COMPLETE CLINICAL RESPONSE WITH CHEMOTHERAPY REGIMEN 182
Good manufacturing practice-grade fibrin gel is useful as a scaffold for human mesenchymal stromal cells and supports in vitro osteogenic differentiation 182
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis 182
Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib 182
A PRACTICAL APPROACH TO THERAPEUTIC DRUG MONITORING OF IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID ELEUKEMIA. THE TIKLET PROTOCOL. 181
Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis 181
90y Ibritumomab Tiuxetan as Initial Treatment for Follicular Lymphoma (ZEUS Protocol). An Italian Cooperative Study Group 180
Unusual morphology in a case of large granular cell leukemia 180
High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naïve lymphocytes and prevents TTV reactivation 180
Early Diagnosis of Neutropenic Enterocolitis by Ultrasound Sonography. 179
No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan 179
Droplet digital PCR represents a new sensitive method for detecting B-RAFV600E mutation at diagnosis and during the follow-up of patients affected by hairy cell leukemia 178
Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup 178
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 178
Precision medicine in lymphoma by innovative instrumental platforms 178
SAHA INHIBITS PROLIFERATION AND INDUCES APOPTOSIS IN A MEGAKARYOBLASTIC CELL LINE AND SYNERGISTICALLY INTERCATCS WITH THE PORTEASOME INHIBITOR BORTEZOMIB. 177
Glycosylated or non-glycosylated G-CSF differently influence human granulocyte functions through RhoA 177
Gelatin/PLLA sponge-like scaffolds allow proliferation and osteogenic differentiation of human mesenchymal stromal cells 177
Morphological analysis of phenotype MDR cell expression: morphofunctional correlations 175
Aggressive Non Hodgkin lymphoma'patients Treated by High Dose Chemotherapy and Immunotherapy Has a Lower Relapse Rate: Results of a Computer Science Analysis. 175
Induction of neutralizing antibodies in CLL patients after SARS-CoV-2 mRNA vaccination: a monocentric experience 174
Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis 174
HISTONE DEACETYLASE INHIBITOR ITF2357 EXERT SIGNIFICANT ANTI-PROLIFERATIVE AND PRO-APOPTOTIC EFFECTS ON THE P39 CELL LINE: A GENE EXPRESSION STUDY 174
Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphisms. 174
Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. 174
A therapy resistant myelodysplastic syndrome characterized by the presence of the rare reciprocal translocation t(3;12)(q26.2;p13) 172
Torquetenovirus (TTV) load is associated with mortality in Italian elderly subjects 172
Pharmacogenetic Study on Multiple Myeloma Patients Treated with DAV Regimen and Autologous Stem Cell Transplantation. 171
P112 gene expression patterns in MDS with del5q before and during lenalidomide treatment 171
SAFETY AND EFFICACY OF 90 Y IBRITUMUMAB TIUXETAN (ZEVALIN) FOR UNTREATED FOLLICULAR NON HODGKIN'S LYMPHOMA (FL) PATIENTS. ITALIAN MULTICENTRIC TRIAL. 171
Immune Reconstitution after Allogeneic Stem Cell Transplantation: a Pilot Flow-Cytometry Study for T-Cell Sub-Populations 171
Totale 23.428
Salva come PNG Salva come JPEG
Categoria #
all - tutte 205.436
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 205.436
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021685 0 0 0 0 0 0 0 0 0 0 0 685
2021/20225.452 163 362 141 344 919 658 158 235 444 150 363 1.515
2022/20235.788 911 812 383 550 573 700 54 462 876 45 356 66
2023/20248.110 603 556 558 365 713 798 231 106 67 3.358 187 568
2024/202514.843 66 563 123 788 1.154 1.257 1.368 947 1.488 1.983 1.620 3.486
2025/202617.558 916 2.329 2.796 1.935 1.566 1.620 2.345 794 892 1.397 822 146
Totale 74.813